Literature DB >> 18180499

International prices and availability of pharmaceuticals in 2005.

Patricia M Danzon1, Michael F Furukawa.   

Abstract

This paper compares pharmaceutical spending, availability, use, and prices in twelve countries in 2005. Drug spending per capita was higher in the United States than in other countries. The United States had relatively high use of new drugs and high-strength formulations; other countries used more of older drugs and weaker formulations. Thus, whether U.S. overall volume of use is lower or higher depends on the measure of volume and type of product. Comprehensive price indexes show foreign prices to be 20-40 percent lower than U.S. manufacturer prices, but only 10-30 percent lower than U.S. public prices. Generics are cheaper in the United States than in other countries.

Mesh:

Substances:

Year:  2008        PMID: 18180499     DOI: 10.1377/hlthaff.27.1.221

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  20 in total

1.  Use of fibrates in the United States and Canada.

Authors:  Cynthia A Jackevicius; Jack V Tu; Joseph S Ross; Dennis T Ko; Daniel Carreon; Harlan M Krumholz
Journal:  JAMA       Date:  2011-03-23       Impact factor: 56.272

2.  Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing?

Authors:  Andreas Gerber; Stephanie Stock; Charalabos-Markos Dintsios
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

3.  Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.

Authors:  Blase N Polite; Jeffery C Ward; John V Cox; Roscoe F Morton; John Hennessy; Ray D Page; Rena M Conti
Journal:  J Oncol Pract       Date:  2014-11       Impact factor: 3.840

4.  Preferred supplier contracts in post-patent prescription drug markets.

Authors:  Carl Rudolf Blankart; Tom Stargardt
Journal:  Health Care Manag Sci       Date:  2016-02-22

Review 5.  Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.

Authors:  Fabrice Smieliauskas; Chun-Ru Chien; Chan Shen; Daniel M Geynisman; Ya-Chen Tina Shih
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

6.  Is American health care uniquely inefficient?

Authors:  Alan M Garber; Johathan Skinner
Journal:  J Econ Perspect       Date:  2008

Review 7.  Ontario's plunging price-caps on generics: deeper dives may drown some drugs.

Authors:  Aslam Anis; Stephanie Harvard; Carlo Marra
Journal:  Open Med       Date:  2011-09-27

8.  Pharmaceutical regulation in Europe and its impact on corporate R&D.

Authors:  Stephan Eger; Jörg C Mahlich
Journal:  Health Econ Rev       Date:  2014-10-03

Review 9.  Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.

Authors:  Angela Acosta; Agustín Ciapponi; Morten Aaserud; Valeria Vietto; Astrid Austvoll-Dahlgren; Jan Peter Kösters; Claudia Vacca; Manuel Machado; Diana Hazbeydy Diaz Ayala; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2014-10-16

10.  Cost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: an empirical approach based on healthcare utilisation databases.

Authors:  Lorenza Scotti; Andrea Arfè; Antonella Zambon; Luca Merlino; Giovanni Corrao
Journal:  BMJ Open       Date:  2014-03-24       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.